Researchers at Tsukuba University have discovered that the increase in regulatory T (Treg) cells, which typically suppress ...

Dr. Simrit Parmar, a Northwestern University-trained oncologist and research scientist, launched Cellenkos Inc., in 2016 to ...

Regulatory T cells (TReg cells) have a central role in immune regulation, but how do they work? In this Review, our current understanding of the suppressive mechanisms used by TReg cells is ...

The findings contradict previous research suggesting high-risk patients with multiple myeloma were more likely to have a ...

When ocrelizumab became the first FDA-approved treatment for early forms of multiple sclerosis (MS) in 2017, it offered ...

Proceeds to support key development milestones, including CMC advancement, initiation of a Phase I clinical trial in the first half of 2026, and strategic expansion of the leadership team ...

Egle Therapeutics, a clinical-stage biotechnology company developing therapies targeting regulatory T cells (Tregs) for immuno-oncology and autoimmune diseases, will present two posters at the ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

In the final part of his Pharma Commerce video interview, Mark Sawicki, PhD, Cryoport Systems’ president and CEO, predicts ...

Rezpegaldesleukin, an investigational interleukin-pathway agonist, demonstrated efficacy and safety for people with moderate ...

Orca-T shows significant promise in reducing chronic graft-vs-host disease and improving survival rates in allogeneic transplant patients with hematologic malignancies.

Cell and gene therapy leaders say the agency’s decision to remove the Risk Evaluation and Mitigation Strategies that had been ...